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Abstract
Probiotics, defined as “living microorganisms that, whether ingested in useful amount, 
may have beneficial effects on human body”, are widely used in various products for 
human use, such as dietary supplements, medical devices and pharmaceutical products. 
The European Directive on medical devices (MDs) (DDM 93/42), also includes those 
MDs containing live microorganisms, particularly probiotics, that may have various des-
tinations of use, including that of assisting the therapy of several human pathologies. In 
this brief note we analyzed the use of probiotics in MDs and how probiotics administra-
tion could represent one of the new frontiers of scientific research on the prevention and 
treatment of various diseases. We’ll analyze the literature on probiotics based MDs, to 
review their major targets in the therapy of some of the most common human patholo-
gies: bacterial vaginosis and vaginitis, atopic dermatitis, infantile colic, obesity, type 2 
diabetes, and pharyngotonsillitis. 
INTRODUCTION
Inside the human body, a large number of commensal 
microorganisms reside, which mainly colonize gastroin-
testinal tract, skin and mouth. The entire population of 
microorganisms (Bacteria, Viruses and Fungi) that live 
inside each individual’s organism or part of it is called 
“microbiota”; “human microbiome” refers instead to the 
collective genomes of these microbes [1]. 
Probiotics are defined as “living microorganisms that, 
whether ingested in useful amount, may have beneficial 
effects on human body” [2]. In the gastrointestinal tract, 
hundreds (100-1000) of different bacterial species of 
probiotics have been isolated [3]: among them, Bifido-
bacterium and Lactobacillus are the most studied genera. 
Probiotics play their beneficial role by several 
mechanisms, including production of antibacterial 
compounds, such as organic acids and bacteriocins, 
enhancement of the epithelial gut barrier function, 
competitive exclusion. Moreover, this bacteria can 
exert their role by modulation of the host innate and 
adaptive immune responses: they can suppress intes-
tinal inflammation via the downregulation of toll-like 
receptors expression, secretion of metabolites that may 
inhibit TNF-a from entering blood mononuclear cells 
and inhibition of NF-kB signaling in enterocytes. The 
activity of probiotics could have an important role to 
elicit measured antimicrobial responses with minimal 
inflammatory tissue damage [4]. 
Probiotics are used as active component in pills, 
beverages, oral or vaginal capsules, or as ingredients in 
several food products, like yogurt [3]. Hence, probiot-
ics could have several usages depending on the product 
which they are part of: pharmacological, medical device 
(MD) or dietary supplement.
The European Directive on medical devices (DDM 
93/42) [5], also includes those MDs containing live mi-
croorganisms, particularly probiotics.
The uses of living microorganisms-based MDs or 
probiotic-based MDs (PbMDs), as currently sold in the 
EU, are several. In this brief note, we’ll focus on their 
major targets in the therapy of some of the most com-
mon human pathologies: bacterial vaginosis and vagi-
nitis, atopic dermatitis, infantile colic, obesity, type 2 
diabetes, and pharyngotonsillitis.
BACTERIAL VAGINOSIS AND VAGINITIS 
The vaginal microbiota (namely, the population of mi-
croorganisms which naturally live in the vagina) is a dy-
namic population able to adapt itself to changes of any 
physiological conditions, e.g. during menstrual cycle 
or pregnancy. Where the physiological conditions un-
dergo to alteration, due to a number of possible causes 
(e.g. constipation, use of aggressive hygienic vaginal 
products), a variation in the vagina microbial popula-
tion composition may occur. This may lead either to 
the migration of microbes from the intestine, or to the 
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entrance of external pathogens, capable to colonize the 
vaginal environment. In such clinical conditions, the 
PbMDs seem to act by disinfecting and reducing the 
growth of pathogens like Candida albicans, Gardnerella 
vaginalis and others, which colonize the female urinary 
tract, providing acidification and hypoxia in the vaginal 
environment [6].
In women affected by vulvovaginal candidiasis, lac-
tobacilli often coexist in the vaginal epithelial together 
with C. albicans, while in women affected by bacterial 
vaginosis such coexistence between lactobacilli and 
pathogens is reduced [7]. Clinical and in vitro studies 
showed the efficacy of some lactobacilli strains against 
C. albicans. Some species, as L. acidophilus, L. rhamno-
sus GR-1 e L. fermentum RC-14, can be used as effective 
preventive agents in women frequently affected by C. 
albicans vulvovaginitis (more than three times per year), 
instead of antifungal agents which cannot be used due 
to their side effects. On the contrary, lactobacilli do not 
show any contraindications [8]. 
Bacterial vaginosis is caused by the uncontrolled 
proliferation of some anaerobic bacteria, as G. vagi-
nalis, Prevotella bivia spp., Bacteroides spp., Peptostrep-
tococcus anaerobius, Mobiluncus. In healthy women, 
different species of aerobic bacteria of the genus Lac-
tobacillus, and in particular L. plantarum, L. rhamnosuse 
and L. acidophilus are predominant, while the above 
mentioned anaerobies are present in a stable and con-
trolled number.
The antagonistic properties of Lactobacillus strains, 
isolated from the vagina of healthy women against the 
majority of pathogens responsible for bacterial vagino-
sis, have been evaluated. Almost all Lactobacillus strains 
showed antagonistic activity against anaerobic bacteria 
such as G. vaginalis, Prevotella biviae, P. anaerobius, while 
only a few demonstrated the capability to inhibit the 
growth of aerobic Gram-positive cocci such as Entero-
coccus faecalis or Staphylococcus aureus [9].
In a recent study, the L. fermentum SK5 strain isolated 
from the vagina of a healthy woman, was tested in vi-
tro to evaluate its probiotic potential. L. fermentum SK5 
showed to have an antagonist activity towards Esche-
richia coli and G. vaginalis [10].
In another in vivo study on a murine vaginal model of 
G. vaginalis, it was shown that the growth of G. vaginalis 
was inhibited in animals when locally treated with a 109 
CFU (colony-forming units)/mL dose of L. fermentum 
L23. Therefore, L. fermentum L23 could be considered 
as a potential biotherapeutic agent for the eradication 
of such bacterium [11].
Thus, such lactobacilli strains can be regarded as very 
good candidates to be used as probiotics for the restor-
ing of the normal microbial communities of the vaginal 
ecosystem [12].
Clinical trials were performed to assess the efficacy 
of oral administration of Lactobacillus paracasei subsp. 
paracasei F19, in association with vaginal suppositories 
containing L. acidofilus, in the treatment of bacterial 
vaginosis and in the prevention of recurrent vaginitis. 
Sixty healthy women, aged 18 to 40, with suspected or 
confirmed bacterial vaginosis were recruited. The in-
volved subjects were randomly divided into 2 groups: 
group A, which was treated with vaginal ovules contain-
ing L. acidophilus, and group B, which received the vagi-
nal ovules plus an oral probiotic containing L. paracasei 
F19. Patients were examined at the end of the 3 months 
therapy, then after a further 3 months. At the end of 
therapy, both groups showed a significant reduction in 
vaginal pH and improvement in subjective symptoms. 
However, for all group A patients, improvement pro-
gressively decreased during the 3 months follow-up, 
while the positive effects were maintained for group 
B even after the 6 months of treatment. Overall, this 
study showed that the use of probiotics is crucial for 
treatment of bacterial vaginosis as alternative to con-
ventional antibiotic therapies [13].
The dominance of lactobacilli in healthy vaginal mi-
crobiota and its depletion in vaginitis has given rise to 
the concept of oral or vaginal therapeutic or preventive 
use of them. Indeed, the preferred route of delivery for 
probiotic lactobacilli is intravaginal. However, some 
authors delivered lactobacilli orally to repopulate the 
vagina, based on the observation that pathogens can 
pass from the gut into the urogenital system, and that 
orally administered Lactobacillus strains were recovered 
from the vagina. It is noteworthy that the capability of 
lactobacilli to colonize the vagina after oral ingestion is 
strictly dependent on their viability and ability to resist 
to gastric acid and bile salts [14].
ATOPIC DERMATITIS 
Atopic dermatitis is a skin inflammation due to both 
hereditary and external factors such as cold weather, 
synthetic clothing, irritating foods.
In children, it is characterized by generally highly pru-
riginous skin lesions, with chronic-relapsing diseases, 
usually appearing for the first time in infants, sponta-
neously healing around 3 years’ age or almost always 
within puberty (rarely lasts until adulthood).
Characteristics and locations of lesions may vary de-
pending on age: in younger child, they may appear as 
red and exudative (i.e.) round patches, located in the 
face (excluding mouthpiece) and in the limbs extensory 
areas, while they may show as yellowish-brown on scalp 
and face. In the older children, dermatitis is located at 
legs and arm folds or around mouth and eyelids, while 
skin appears dry.
Atopic dermatitis may be based on a constitutional 
predisposition, ever if some triggers may occur (e.g., 
cold climate, synthetic or wool garments, dust, saliva, 
irritating foods like tomatoes and citrus fruits), alter-
ing skin barrier and then causing dryness, itching and 
hyperactivity.
To understand the beneficial effects of probiotics over 
atopic dermatitis, several clinical trials have been per-
formed.
One of these trials was performed to evaluate the ef-
ficacy of L. paracasei , L. fermentum alone and in combi-
nation, on disease evolution, quality of life and atopic 
dermatitis immune biomarkers. A randomized double-
blind study was carried out on 220 subjects, aged be-
tween 1 and 18, affected by moderate/severe atopic 
dermatitis. The subjects randomly took L. paracasei , L. 
fermentum, both and placebo for 3 months. The results 











showed that L. paracasei and L. fermentum LF probiotics 
mixtures supplemented diet, lead to an improvement in 
the disease [15].
According to another trial, the efficacy of a L. sali-
varius LS01 (DSM 22775) supplemented diet for the 
treatment of dermatitis in children was evaluated. As 
atopic dermatitis is a chronic inflammatory and itchy 
skin disease with multifactorial etiopathology, some 
studies suggest that probiotics performances can be 
enhanced by an immune system modulating through 
the improvement of intestinal bacterial flora compo-
sition. Forty-three subjects, aged between 0 and 11 
(ratio M/F = 1:1), were treated or not treated with L. 
salivarius strain LS01 probiotic. Clinical efficacy of pro-
biotic therapy evaluation was based on the assessment 
of changes in the itching index and SCORAD (Scoring 
Atopic Dermatitis), a score indicating atopic dermatitis 
severity. Four weeks after the onset of treatment, pa-
tients treated with probiotics showed a significant im-
provement in clinical parameters (i.e., SCORAD and 
itchy values) compared to untreated ones. Hence, L. 
salivarius LS01 seems to improve the quality of life of 
children with atopic dermatitis [16].
In this view, a recent review reported that atopic 
conditions are associated with immunoglobulin E-me-
diated immune responses, and that probiotic related 
improvements generally have multiple targets. Indeed, 
it is known that  probiotic supplementation alters the 
intestinal microbiome in a way that improves skin per-
meability and barrier functions, thus modulating the 
immune response [17].
INFANTILE COLIC
Infantile colic (IC) is a syndrome that occurs dur-
ing the first four months of life, characterized by par-
oxysmal, excessive and inconsolable crying in healthy 
children without identifiable cause. According to some 
studies, the prevalence of colic in infants ranges from 
3% to 40% [18].
IC causes are still unknown and no effective protocol 
for their treatment has been planned, yet. Many causal 
hypotheses have been prepared, which can be sum-
marized in organic and/or behavioral causes (perhaps, 
related to mothers’ excess anxiety). Organic causes 
might be attributable to abnormalities in gastrointes-
tinal function or allergic disorders. In the latter case, 
the most frequently used measures are the use of hy-
drolyzed proteins added milk (hypoallergenic milk), the 
use of herbal infusions or a specific pharmacological 
therapy. A further approach to this problem could be 
identified in synbiotics, as the result of the synergistic 
combination of probiotics and prebiotics.
In 1995, prebiotics were defined by Gibson and 
Roberfroid as non-digested food components which, 
through the stimulation of growth and/or activity of a 
single type or a limited amount of microorganisms re-
siding in the gastrointestinal tract, improve the health 
condition of a host [19]. In 2004, the definition was 
updated and prebiotics were defined as selectively fer-
mented components allowing specific changes in the 
composition and/or activity of microorganisms in the 
gastrointestinal tract, beneficial for host’s health and 
wellbeing [20]. Finally, in 2007, FAO/WHO experts 
described prebiotics as a nonviable food component 
that confers a health benefit on the host associated with 
modulation of the microbiota [21].
Prebiotics may be used as an alternative to probiotics 
or as an additional support for them. However different 
prebiotics will stimulate the growth of different indig-
enous gut bacteria. Prebiotics have enormous potential 
for modifying the gut microbiota, but these modifica-
tions occur at the level of individual strains and species 
and are not easily predicted a priori. Many reports on 
the beneficial effects of prebiotics on human health are 
available.
Scientific studies have shown prebiotics ability to 
improve probiotics, providing a specific substrate for 
already existing intestinal bacterial flora. In a double-
blind, randomized clinical trial, the efficacy of synbi-
otics was evaluated against the reduction of average 
baby’s crying time over a 30 days’ period from the start 
of treatment. The synbiotic administered contained 
109 CFUs of: L. casei, L. rhamnosus, Streptococcus ther-
mophilus, Bifidobacterium breve, L. acidophilus, Bifidobac-
terium infantis, L. bulgaricus and fructo-oligosaccharides 
(FOS). No adverse effect were reported. It was found 
that the use of a blend of seven probiotic strains plus 
FOS significantly reduced colic symptoms, instead of 
those subjects who took placebo [18].
Safety of probiotics and synbiotics in newborns
Another double-blind, randomized clinical trial, 
evaluated the food safety of synbiotics in infants, by 
giving then the synbiotics during the last four weeks 
before their birth, then by feeding their mother until 
the sixth month of life of the newborn baby. Recruiting 
of subjects were made considering pregnant mothers 
whose children were highly likely to develop food aller-
gies. Pregnant mothers, randomly took either a blend 
of 4 probiotic species (L. rhamnosus GG, L. rhamnosus 
LC705, Bifidobacterium breve BB99 and Propionibacte-
rium freudenreichii ssp. shermanii) or a placebo, plus 0.8 
g of galacto-oligosaccharides or a placebo daily. Safety 
data were obtained from clinical trials and interviews 
in follow-up visits to 3, 6, 12, and 24 months. Growth 
data were collected for each item. Growth was normal 
for all newborns. During 6 months of intake, newborns 
in the synbiotics group had to take less antibiotics than 
the placebo group (23% vs 28%). During the follow-up 
period, respiratory infections occurred less often in the 
group that took synbiotics. The authors conclude that 
feeding infants with synbiotics may be retained as safe 
and seems to increase resistance to respiratory infec-
tions during the first 2 years from childbirth [22].
OBESITY
It is known to be a correlation between alteration 
of the microbial flora and obesity [23]. Consequent-
ly, among the therapeutic strategies useful as obesity 
treatment adjuvants, there are probiotics, which help 
to maintain the composition balance of the intestinal 
microbial [24].
A randomized, double-blind, placebo-controlled trial 
was carried out to evaluate the effects of probiotics 











when combined with Bofutsushosan (BTS), a Japanese 
herbal drug, widely used in East Asia as anti-obesity 
treatment of overweight patients. Probiotics were used 
to test their ability to modulate intestinal flora, intesti-
nal permeability, and endotoxin levels, factors that may 
be related to obesity. Bofutsushosan was administered 
in the form of plant extracts (Tsumura & Co., Japan). 
Probiotics were taken orally in capsules of Duolac 7 
(Cell Biotech, Gimpo, Korea) containing 5×109 CFUs 
total of: S. thermophilus (KCTC 11870BP), L. plantarum 
(KCTC 10782BP), L. acidophilus (KCTC 11906BP), 
L. rhamnosus (KCTC 12202BP), B. lactis (KCTC 
11904BP), B. longum (KCTC 12200BP) and B. breve 
(KCTC 12201BP). Fifty patients with a high body mass 
index (> 25 kg/m2) and a waist circumference (> 85) 
cm were recruited. Subjects were randomly assigned to 
receive Bofutsushosan and probiotic (n = 25) or Bofut-
sushosan and placebo (n = 25) for 8 weeks. At early trial 
stage and after eight weeks of treatment, relevant pa-
rameters such as body composition, metabolic markers, 
endotoxin levels, intestinal permeability and number of 
fecal bacteria in the feces were evaluated.
Correlation between the composition of intestinal 
microbial flora and change in body composition indi-
cates that probiotics can affect energy metabolism in 
obesity. Moreover, the correlation between endotoxin 
levels and body weight reduction indicates that probi-
otics can play an important role in preventing the ac-
cumulation of endotoxins, which can lead to intestinal 
dysbiosis associated to obesity [25].
TYPE 2 DIABETES
Intestinal microbiota, that is, the bacterial microflora 
that inhabits our intestine as a true human microbial or-
gan, acts as a useful and important system for our body, 
but whether affected by anomalies or alterations, it can 
be related to the onset of diabetes mellitus type 2. Re-
cent studies have found a relationship between diabetes 
and intestinal microbiota [26].
Intestinal bacteria have been shown to play a role in 
the genesis of obesity, diabetes, and cardiovascular dis-
ease. It is known to be a close association between obe-
sity and type 2 diabetes. Many studies have found that 
both overweight and type 2 diabetes are characterized 
by an intestinal dysbiosis.
A double-blind, randomized clinical trial, was de-
signed to determine the influence of multiple-species 
probiotic supplements on certain metabolic parameters 
such as hs-CRP (high sensitivity C-reactive protein) and 
stress oxidative in diabetic patients. Fifty-four diabetic 
patients, aged 35 to 70, were recruited and randomly 
administered with either a multi-species probiotic or a 
placebo (27 patients each) over 8 weeks. The synbiotic 
multiple-species consisted of 7 strains of lyophilized vi-
tal probiotics: L. acidophilus (2 × 109 CFU), L. casei (7 
× 109 CFU), L. rhamnosus (1.5 × 109 CFU), L. bulgaricus 
(2 × 108 CFU), B breve (2 × 1010 CFU), B. longum (7 × 
109 CFU), S. thermophilus (1.5 × 109 CFU), and 100 mg 
of fructo-oligosaccharides.
Blood samples were taken as fasting and after probi-
otics intake to measure metabolic parameters, hs-CRP, 
and oxidative stress biomarkers, including total anti-
oxidant plasma capacity and total glutathione (GSH). 
Compared to placebo, an eight weeks multiple-type 
synbiotic intake by diabetic patients prevented an in-
crease in fasting glycemia and resulted in a decrease in 
serum hs-CRP and an increase in GSH in total plasma 
[27].
PHARYNGOTONSILLITIS
Acute pharyngotonsillitis are very common diseases, 
mainly caused by viruses (adenovirus, influenza virus, 
parainfluenza viruses, rhinovirus, and synthetic respira-
tory virus). Among bacteria, Beta-hemolytic strepto-
cocci (GABHS) or Streptococcus pyogenes are the most 
common cause of acute pharyngeal tonsillitis, which ac-
counts for about 15-30% of cases in children and 5-10% 
of cases in adults. The aims of antibiotic therapy against 
GABHS pharyngotonsillitis in adult are to prevent 
complications, to shorten the clinical course and the 
duration of disease’s infectivity. Due to the increased 
bacterial resistance to antibiotics, the therapeutic use 
of probiotics could be very interesting. 
Recent clinical studies showed that probiotics can be 
effective in the treatment of allergic rhinitis [28], ec-
zema and allergies [29, 30].
A meta-analysis of ten randomized controlled trials 
showed that use of probiotics is advantageous com-
pared to placebo for the prevention of acute upper re-
spiratory tract infections [31].
The most commonly used genera include Lactoba-
cillus and/or Bifidobacterium, but the list of probiotic 
microorganisms is continuously growing, including a 
non-pathogenic strain of Escherichia coli (E. coli Nissle 
1917), Clostridium butyricum, Saccharomyces boulardii (a 
non-pathogenic yeast strain), and Streptococcus salivar-
ius. S. salivarius is the predominant bacterial species of 
the oropharyngeal tract of adults [32]. The presence of 
S. salivarius inhibits the colonization and proliferation 
of pathogenic and competing microorganisms [33]. In 
pediatric patients, frequently suffering by throat infec-
tions, S. salivarius, isolated from nasopharynge, was 
shown to produce bacteriocins with anti-Streptococcus 
pyogenes activity [33, 34]. S. salivarius was shown to be 
safe for ingestion [35].
CONCLUSIONS
Although probiotics have been deeply studied, many 
aspects still need to be clarified, such as competition 
for energy substrates and intestinal wall adhesion sites. 
Obviously, like all substances that are administered to 
humans, probiotics must have specific characteristics 
that make them suitable for use.
First of all, a probiotic must be safe for humans. Ac-
cording to safety analysis carried out by EFSA (Euro-
pean Food Safety Authority), a list of safe species has 
been drawn up. Then, a probiotic must reach the in-
testine alive and vital and here it must be able to mul-
tiply. It is important to emphasize that characteristics 
and mechanisms of action are different from one strain 
to another. Therefore, to choose a probiotic suitable to 
each particular need, the specific effects (assessed by 
appropriate clinical trials) of the different strains avail-
able must be known.











In conclusion, the administration of probiotics may 
be probably considered as the new frontier of scientific 
research on prevention and treatment of various dis-
eases, ranging from children’s respiratory and allergic 
disorders to severe metabolic manifestations such as 
adult’s insulin-dependent diabetes mellitus.
Of course, new studies are required in order to assess 
which probiotics strains and species should be used, 
depending on the type of manifestations and timing 
of intervention (i.e. prenatal, neonatal, weaning, early 
childhood, adolescence); nevertheless, probiotics seems 
to be a really promising remedy for health.
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